RE:Today's NR and the Unspoken analyst report
I find it odd that this release is nearly identical to what the $5, $10 and $22 analyst was projecting for early 2014. With the exception of the words "but" and "soon" this is a very positive release.
The trial is not being stopped for safety or efficacy reasons, but enrollment requirements are being recalculated, presumbly to expedite the trials completion. If the DSMB had bad news for Spectral the trial would have been stopped cold, not allowed to continue and quite possibly be accelerated through to completion.
Its a pretty gunshy crowd when "but" and "soon" can drive a 35% hair cut.
It would seem to me that this rather Spartan, but otherwise positive, news release is being "played up" a little bit.